Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of targeted intraprostatic topsalysin for localized prostate cancer
2014-003386-22Phase 2Completed
- Sponsor
- Sophiris Bio Inc.
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topsalysin in prostate cancer (PCa), sponsored by Sophiris Bio Inc. Primary endpoint: Safety and tolerability of PRX302. Started Oct 2014; status: completed.
02
Drugs
topsalysin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-003386-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003386-22.